Description

Simple

Clinical

Overview

Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Gavestinel
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Adenine
The metabolism of Gavestinel can be decreased when combined with Adenine.
Amitriptyline
The metabolism of Gavestinel can be decreased when combined with Amitriptyline.
Atazanavir
The metabolism of Gavestinel can be decreased when combined with Atazanavir.
Carbamazepine
The metabolism of Gavestinel can be increased when combined with Carbamazepine.
Dacomitinib
The metabolism of Gavestinel can be decreased when combined with Dacomitinib.
Dasabuvir
The metabolism of Gavestinel can be decreased when combined with Dasabuvir.
Deferasirox
The metabolism of Gavestinel can be decreased when combined with Deferasirox.
Desogestrel
The metabolism of Gavestinel can be increased when combined with Desogestrel.
Diflunisal
The metabolism of Gavestinel can be decreased when combined with Diflunisal.
Dovitinib
The metabolism of Gavestinel can be decreased when combined with Dovitinib.
Efavirenz
The metabolism of Gavestinel can be increased when combined with Efavirenz.
Eltrombopag
The metabolism of Gavestinel can be decreased when combined with Eltrombopag.
Enasidenib
The metabolism of Gavestinel can be decreased when combined with Enasidenib.
Erlotinib
The metabolism of Gavestinel can be decreased when combined with Erlotinib.
Ertugliflozin
The metabolism of Gavestinel can be decreased when combined with Ertugliflozin.
Ethinylestradiol
The metabolism of Gavestinel can be increased when combined with Ethinylestradiol.
Flunitrazepam
The metabolism of Gavestinel can be decreased when combined with Flunitrazepam.
Flurbiprofen
The metabolism of Gavestinel can be decreased when combined with Flurbiprofen.
Fosphenytoin
The metabolism of Gavestinel can be decreased when combined with Fosphenytoin.
Fostamatinib
The metabolism of Gavestinel can be decreased when combined with Fostamatinib.
1 References
  1. 1 . Warach S, Kaufman D, Chiu D, Devlin T, Luby M, Rashid A, Clayton L, Kaste M, Lees KR, Sacco R, Fisher M: Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy. Cerebrovasc Dis. 2006;21(1-2):106-11. Epub 2005 Dec 9.PubMed: 16340185